Beijing Shuanglu Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") has recently received the drug registration certificate for Rivastigmine Tartrate Oral Solution (brand name: Yizhi®) issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The relevant information about the drug is as follows:
002038SZSE
Announcement on Obtaining the Drug Registration Certificate for Rivastigmine Tartrate Oral Solution
✨ AI Summary
Beijing Shuanglu Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the drug registration of Rivastigmine Tartrate Oral Solution (brand name: Yizhi®). The product is indicated for treating mild to moderate Alzheimer's and Parkinson's disease dementia. The approval enhances the company's product portfolio in geriatric medicine, although sales may be affected by industry policies and market conditions.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.